Full-Time

R&D System & Access Management Specialist

Confirmed live in the last 24 hours

Deadline 7/16/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Junior, Mid

Hyderabad, Telangana, India

In Person

Category
Lab & Research
Medical Research
Requirements
  • Previous system role and access management or ownership experience required.
  • Ideally trained in various Clinical, Development and regulatory systems including Veeva Vault, RIMs, CTMS Tools, iEnvision, etc.
  • Ability to quickly learn new systems, interfaces and tools.
  • Familiarity with pharmaceutical processes, product development, and regulatory requirements.
  • Understanding of drug development stages, clinical trials, and manufacturing processes.
  • Effective verbal and written communication to convey system related information.
  • Collaboration with R&D system owners and stakeholders.
  • Strong problem-solving skills for evaluating proposed changes.
  • Identification of risks, benefits, and potential obstacles.
  • Experience working cross-functionally with R&D teams and Digital teams.
  • Comfort with evolving processes and frequent adjustments during development.
  • Bachelor’s degree or equivalent, specifically in the digital or IT space.
  • Excellent communications skills, both verbal and written in English. French and German are a plus.
Responsibilities
  • Analyze user access needs and determine appropriate access levels, including creating standards for various roles across our teams and systems.
  • Set up and maintain user profiles, roles, and access rights in our R&D systems.
  • Manage the demand process and the follow-up of demands and incidents.
  • Support the user access cleaning and compliance process.
  • Contribute to the implementation of Role and Access User Management Process and data for the deployment of new global R&D Applications across functions.
  • Monitor access activities to identify any issues, unauthorized access/ attempts, system outages or other issues impacting accessibility and security.
  • Perform regular audits to ensure access rights align with job roles and responsibilities.
  • Ensure compliance with quality/ security standards and data privacy regulations.
  • Contribute to incident resolution with Digital function.
  • Contribute to simplify and accelerate the process.
  • Generate KPIs and dashboard.
  • Develop and maintain effective relationships with all internal / external customers: internal critical stakeholders (R&D and Digital community) and external stakeholders (CROs, contractors, Investigator sites).
  • Support User Role and Access Management Team Leader in understanding of stakeholders needs & expectations and provide end to end solutions for User Roles & Access Management global activities across R&D.
  • Liaise with R&D system owners and Digital Teams to manage new and existing user roles.
  • Act as the key point of contact for all questions and business-related issues for User role.
  • Resolve access issues promptly and maintain all service level agreements.
  • Collaborate with Digital and security teams to improve access management systems.
  • Contribute to Roles and Use Access Management R&D Network.
  • Develops weekly and monthly status reports for management, capacity planning and new projects.
  • Develop and maintain documentation related to roles and access management processes (Operational Business Documents, & Training documents).
  • Train managers & internal and external requesters / end-users.
  • Provide training to users on access management policies and procedures.
Desired Qualifications
  • French and German are a plus.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments worldwide. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...